查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
T 細胞療法市場規模、份額和趨勢分析報告，按方式、按療法（CAR T 細胞、腫瘤浸潤淋巴細胞）、按適應症（血液惡性腫瘤（淋巴瘤））、按分部預測，2023-2030 年
市場調查報告書
商品編碼
1233261

T 細胞療法市場規模、份額和趨勢分析報告，按方式、按療法（CAR T 細胞、腫瘤浸潤淋巴細胞）、按適應症（血液惡性腫瘤（淋巴瘤））、按分部預測，2023-2030 年

T-cell Therapy Market Size, Share & Trends Analysis Report By Modality, By Therapy (CAR T-cell, Tumor-Infiltrating Lymphocytes), By Indication (Hematologic Malignancies (Lymphoma)), And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 200 Pages | 商品交期: 2-10個工作天內

價格

T 細胞療法市場增長和趨勢

Grand View Research, Inc. 的最新報告顯示，到 2030 年，全球 T 細胞療法市場規模將達到 308.3 億美元，2023 年至 2030 年的 CAGR 將達到 17.6%，預計將創歷史新高

Kymriah 和 Yescarta 的主要批准推動了市場進程。 此類療法的推出增強了該領域創新的現金流，從而促進了市場增長。

從一線乾細胞移植和化療到嵌合抗原受體 (CAR) T 細胞療法的患者偏好不斷變化，預計這將提供市場增長機會。 與此同時，正在測試 T 細胞療法的疾病清單也在不斷增加。 隨著對其他領域的投資不斷增加，腫瘤疾病備受關注。

多發性骨髓瘤患病率上升、白血病和淋巴瘤患病率上升導致 CAR-T 細胞療法得到廣泛採用，並正在推動市場增長。 根據白血病和淋巴瘤協會 (LLS) 的數據，美國估計約有 54,000 名 20 歲及以上的兒童和青少年患有淋巴瘤、白血病、骨髓瘤和骨髓增生異常綜合徵 (MDS)。 文件稱，2021年美國將新增確診癌症患者約1898160人，其中白血病、淋巴瘤和骨髓瘤的新增發病率為9.8%。

隨著新療法的推出，臨床試驗活動的增加預計將推動未來幾年的市場增長。 例如，2021 年 12 月，諾華宣布推出其下一代 CAR-T 平台 T-ChargeTM，該平台將作為公司管道中許多新的研究性 CAR-T 細胞療法的基礎。 YTB323（抗 CD19）和 PHE885（抗 BCMA）是第一個在此平台上設計的諾華 CAR-T 細胞治療藥物，諾華將在 2021 年第 63 屆美國血液學會年會暨博覽會（ASH）上展示它已完成.

針對非血液系統惡性腫瘤的 CAR T 療法的開發受到抗原問題和相關毒性問題的嚴重阻礙。 為了克服這一困難並提高 T 細胞療法在腦腫瘤和黑色素瘤等適應症中的利用率，各大公司正在利用數據驅動的方法來研究這一領域。

T 細胞療法市場報告要點

  • 從形式上看，由於臨床試驗中有大量 T 細胞療法產品，基於研究的 T 細胞療法市場預計將佔據很大份額。
  • 由於監管機構批准的產品數量不斷增加，預計未來幾年商業化 T 細胞療法將顯示出巨大的市場份額。
  • 按產品類型劃分，由於 CAR-T 療法產品的臨床試驗增加，CAR-T 細胞療法在 2022 年佔據了該細分市場的主導地位。 此外，越來越多地使用這些療法治療各種癌症有望推動該領域的增長。
  • 血液系統惡性腫瘤在 2022 年佔據了適應症部分的主導地位。 為了治療淋巴瘤和急性淋巴細胞白血病 (ALL)，CAR T 細胞療法最常見的靶標是 B 細胞上的 CD19，這導致五種 CAR T 療法獲得批准。
  • 北美在全球市場中佔有壓倒性的份額。 該地區的增長歸因於臨床試驗的增加、強有力的研究和監管批准的增加，這些療法的採用率增加。

內容

第一章研究方法論

  • 信息採購
  • 信息或數據分析
  • 市場製定和驗證

第 2 章執行摘要

  • 競爭環境
  • 市場概況
  • 細分市場展望

第 3 章市場變量、趨勢和範圍

  • 2020 年治療類型滲透和增長前景圖
  • T 細胞療法 - 市場動態
    • 市場驅動因素分析
      • 增加對用於治療疾病的過繼性 T 細胞轉移方法的投資
      • 市場參與者之間的競爭加劇
      • Kymriah 和 Yescarta 在不同國家/地區獲得批准
      • 針對實體瘤的 CAR-T 細胞療法的開發
      • 製造過程中的技術進步
    • 市場製約因素分析
      • 與基因治療相關的監管、科學和倫理問題
      • 昂貴的醫療費用
      • CAR T 限制
    • 機會分析
      • 擴大細胞和基因治療設施
      • 增加對基因和細胞療法的全球資助
      • 在病毒和非病毒載體製造領域的持續發展
  • 監管狀況
    • 當前和未來可能獲得的批准
    • 降低風險和安全監控框架
    • 當地監管框架
      • 美國
      • 歐洲
      • 中國
      • 日本
  • 過繼細胞療法 (ACT) 定價和支付模式
    • 保險範圍
    • 基於價值的價格基準
    • 替代支付策略
  • 專利情況
  • 交易、籌款、夥伴關係和協作
    • 許可協議
    • 併購交易
    • 合作與夥伴關係
  • 管道分析
    • 臨床試驗情況
  • 公司地理分佈圖
  • CD19 定向 CART 療法和其他 T 細胞療法的競爭格局
  • T 細胞療法市場 - SWOT 因素分析（政治和法律、經濟、技術）
    • 政治形勢
    • 經濟狀況
    • 社交情況
    • 技術概況
  • 行業分析 - 搬運工
    • 供應商的議價能力
    • 買家的議價能力
    • 替代威脅
    • 來自新進入者的威脅
    • 競爭公司之間的敵對關係

第 4 章 T 細胞治療市場：模式估計和趨勢分析

  • T 細胞療法市場：模式變化分析
  • 研究
  • 產品

第 5 章 T 細胞療法市場分類：治療類型估計和趨勢分析

  • T 細胞療法市場：治療類型的變化分析
  • CAR T 細胞療法
  • 基於 T 細胞受體 (TCR)
  • 基於腫瘤浸潤淋巴細胞 (TIL)

第 6 章 T 細胞療法市場分類：適應症估計和趨勢分析

  • T 細胞療法市場：適應症波動分析
  • 血液系統惡性腫瘤
    • 淋巴瘤
    • 白血病
    • 骨髓瘤
  • 實體瘤
    • 黑色素瘤
    • 大腦和中樞神經系統
    • 肝癌
    • 其他
  • 其他

第 7 章 T 細胞療法市場分類：按方式、治療類型和適應症進行區域估計和趨勢分析

  • 北美
    • SWOT 分析
    • 美國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 加拿大
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
  • 歐洲
    • SWOT 分析
    • 德國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 英國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 法國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 意大利
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 西班牙
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
      • 2018-2030 年西班牙 T 細胞療法市場估計和預測（百萬美元）
    • 丹麥
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 瑞典
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 挪威
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
  • 亞太地區
    • SWOT 分析
      • 主要區域動態
    • 日本
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 中國
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 印度
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 韓國
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 澳大利亞
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 泰國
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
  • 拉丁美洲
    • SWOT 分析
    • 主要地區動態
    • 巴西
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 墨西哥
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 阿根廷
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
  • 中東和非洲 (MEA)
    • SWOT 分析
    • 主要地區動態
    • 南非
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 沙特阿拉伯
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 阿拉伯聯合酋長國
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 科威特
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景

第八章競爭格局

  • 戰略框架
  • 公司簡介
    • 諾華公司
      • 公司簡介
      • 愛貝克思公司
      • 財務業績
      • 產品基準
      • 戰略舉措
    • 吉利德科學
      • 公司簡介
      • 風箏製藥
      • 財務業績
      • 產品基準
      • 戰略舉措
    • 藍鳥生物公司
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • TCR2 Therapeutics Inc.
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • 索倫托療法
      • 公司簡介
      • 產品基準
      • 戰略舉措
    • 命運療法
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • 默克公司
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • 輝瑞公司
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • 安進
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • 新基公司
      • 公司簡介
      • 朱諾療法
      • 財務業績
      • 產品基準
      • 戰略舉措
Product Code: GVR-3-68038-685-1

T-cell Therapy Market Growth & Trends:

The global T-cell therapy market size is expected to reach USD 30.83 billion by 2030 and is expected to register a CAGR of 17.6% from 2023 to 2030 according to a new report by Grand View Research, Inc. The landmark approval of Kymriah and Yescarta have boosted advancements in the market. The launch of such therapies has strenghtned cash flow for innovation in this area resulting in market growth.

The shifting patients' preference from first-line stem cell transplant and chemotherapy towards chimeric antigen receptor (CAR) T cell therapy is expected to create growth opportunities for the market growth. On the other hand, the number of diseases that T-cell therapies are being tested on is constantly growing. With increasing investments in other areas, oncological illnesses are the focus of significant interest.

Rise in the prevalence of multiple myeloma and the rise in incidences of leukemia and lymphomia resulted in high adoption of CAR-T cell therapy, which boosts market growth. According to the Leukemia & Lymphoma Society (LLS), estimated around 54,000 children and adolescents above 20 years in the U.S. have lymphoma, leukaemia, myeloma,and myelodysplastic syndromes (MDS). Moreover, the same source stated that around 1,898,160 new cancer cases will be diagnosed in the U.S. in 2021, with new instances of leukaemia, lymphoma, and myeloma likely to represent 9.8% of those cases.

An increase in clinical trial activity along with new therapy launches is expected to boost the market growth in the coming years. For instance, in December 2021, Novartis declared to launch T-ChargeTM, its next-generation CAR-T platform, which will be the basis for a number of novel investigational CAR-T cell therapies in the company's pipeline. The first Novartis CAR-T cell treatments created with this platform, YTB323 (anti-CD19) and PHE885 (anti-BCMA), were presented by Novartis at the 63rd American Society of Hematology Annual Meeting & Exposition (ASH) 2021.

The development of CAR T treatments for non-hematological malignancies has been significantly hampered by the antigen concerns and associated toxicity issues. To overcome the difficulty and increase the use of T-cell treatment in indication types such as brain cancer and melanoma, key players are utilising a data-driven approach to research this area.

T-cell Theraphy Market Report Highlights:

  • By Modality, the research-based market for T-cell therapies is expected to occupy the larger share of market space due to high number of T-cell therapy products under clinical trials.
  • Commercialized T-cell therapies are expected to show significant market share in the coming years owing to the increase in the number of product approval from the regulatory body.
  • By therapy type, CAR-T cell therapy dominated the segment in 2022 owing to the increase in clinical trials for CAR-T therapy products. Moreover, an increase in the usage of these therapies in different cancer is expected to boost segment growth.
  • Haematological malignancies dominated the indication segment in 2022. In order to treat lymphoma and acute lymphocytic leukaemia (ALL), the most common target of CAR T-cell therapies is CD19 on B-cells, which has led to the approval of five different CAR T therapies.
  • North America dominated the overall global market. The regional growth is attributed to the increasing clinical trials, strong research, and increasing regulatory approval, resulting increase in the uptake of these therapies.

Table of contents

Chapter 1 Research Methodology

  • 1.1 Information Procurement
  • 1.2 Information or Data Analysis
  • 1.3 Market Formulation & Validation

Chapter 2 Executive Summary

  • 2.1 Competition Milieu
  • 2.2 Market Snapshot
  • 2.3 Segment Outlook

Chapter 3 Market Variables, Trends, & Scope

  • 3.1 Penetration & Growth Prospect Mapping for Therapy Type, 2020
  • 3.2 T-Cell Therapy - Market Dynamics
    • 3.2.1 Market driver analysis
      • 3.2.1.1 Rising investment in adoptive T cell transfer approaches of disease treatment
      • 3.2.1.2 Growing competition among market players
      • 3.2.1.3 Approval of Kymriah and Yescarta across various countries
      • 3.2.1.4 Developments in CAR T-cell therapy for solid tumors
      • 3.2.1.5 Technological advancements in manufacturing process
    • 3.2.2 Market restraint analysis
      • 3.2.2.1 Regulatory, scientific, and ethical challenges associated with gene therapy
      • 3.2.2.1 High prices of therapies
      • 3.2.2.2 CAR T limitations
    • 3.2.3 Opportunity analysis
      • 3.2.3.1 Facility expansion for cell and gene therapies
      • 3.2.3.1 Rising global financings in gene and cell therapy arena
      • 3.2.3.2 Ongoing developments in viral & non-viral vector manufacturing arena
  • 3.3 Regulatory Landscape
    • 3.3.1 Current and potential future approvals
    • 3.3.2 Frameworks for risk mitigation and safety monitoring
    • 3.3.3 Regulatory framework, by geography
      • 3.3.3.1 U.S.
      • 3.3.3.2 Europe
      • 3.3.3.3 China
      • 3.3.3.4 Japan
  • 3.4 Pricing and Payment Models for Adoptive Cellular Therapies (ACT)
    • 3.4.1 Insurance coverage
    • 3.4.2 Value-based price benchmarks
    • 3.4.3 Alternate payment strategies
  • 3.5 Patent Landscape
  • 3.6 Deals, Funding's, Partnerships and Collaborations
    • 3.6.1 Licensing deals
    • 3.6.2 Merger & acquisition deals
    • 3.6.3 Collaboration & partnerships
  • 3.7 Pipeline Analysis
    • 3.7.1 Clinical trial landscape
  • 3.8 Geographic Mapping of Companies
  • 3.9 Competitive Landscape for CD19­directed CAR­T Therapies and Other T-cell therapies
  • 3.10 T-cell Therapy Market - SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
    • 3.10.1 Political landscape
    • 3.10.2 Economic landscape
    • 3.10.3 Social landscape
    • 3.10.4 Technology landscape
  • 3.11 Industry Analysis - Porter's
    • 3.11.1 Supplier bargaining power
    • 3.11.2 Buyer bargaining power
    • 3.11.3 Substitution threat
    • 3.11.4 Threat from new entrant
    • 3.11.5 Competitive rivalry

Chapter 4 T-cell Therapy Market: Modality Estimates & Trend Analysis

  • 4.1 T-cell Therapy Market: Modality Movement Analysis
  • 4.2 Research
    • 4.2.1 Global research-based T-cell therapy market, 2018 - 2030 (USD Million)
  • 4.3 Commercialized
    • 4.3.1 Global commercial T-cell therapy market, 2018 - 2030 (USD Million)

Chapter 5 T-cell Therapy Market Categorization: Therapy Type Estimates & Trend Analysis

  • 5.1 T-cell Therapy Market: Therapy Type Movement Analysis
  • 5.2 CAR T-cell Therapy
    • 5.2.1 Global CAR T-cell Therapy market, 2018 - 2030 (USD Million)
  • 5.3 T Cell Receptor (TCR)-based
    • 5.3.1 Global T Cell Receptor (TCR)-based therapy market, 2018 - 2030 (USD Million)
  • 5.4 Tumor Infiltrating Lymphocytes (TIL)-based
    • 5.4.1 Global Tumor Infiltrating Lymphocytes (TIL)-based therapy market, 2018 - 2030 (USD Million)

Chapter 6 T-cell Therapy Market Categorization: Indication Estimates & Trend Analysis

  • 6.1 T-cell Therapy Market: Indication Movement Analysis
  • 6.2 Hematologic Malignancies
    • 6.2.1 Global T-cell therapy market for hematologic malignancies, 2018 - 2030 (USD Million)
    • 6.2.2 Lymphoma
      • 6.2.2.1 Global T-cell therapy market for lymphoma, 2018 - 2030 (USD Million)
    • 6.2.3 Leukemia
      • 6.2.3.1 Global T-cell therapy market for leukemia, 2018 - 2030 (USD Million)
    • 6.2.4 Myeloma
      • 6.2.4.1 Global T-cell therapy market for myeloma, 2018 - 2030 (USD Million)
  • 6.3 Solid Tumors
    • 6.3.1 Global T-cell therapy market for solid tumors, 2018 - 2030 (USD Million)
    • 6.3.2 Melanoma
      • 6.3.2.1 Global T-cell therapy market for melanoma, 2018 - 2030 (USD Million)
    • 6.3.3 Brain & Central Nervous System
      • 6.3.3.1 Global T-cell therapy market for brain & central nervous system, 2018 - 2030 (USD Million)
    • 6.3.4 Liver cancer
      • 6.3.4.1 Global T-cell therapy market for liver cancer, 2018 - 2030 (USD Million)
    • 6.3.5 Others
      • 6.3.5.1 Global T-cell therapy market for other cancer forms, 2018 - 2030 (USD Million)
  • 6.4 Others
    • 6.4.1 Global T-cell therapy market for others, 2018 - 2030 (USD Million)

Chapter 7 T-cell Therapy Market Categorization: Regional Estimates & Trend Analysis, by Modality, Therapy Type & Indication

  • 7.1 North America
    • 7.1.1 SWOT Analysis
      • 7.1.1.1 North America T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.1.2 U.S.
      • 7.1.2.1 Key country dynamics
      • 7.1.2.2 Target disease prevalence
      • 7.1.2.3 Competitive scenario
      • 7.1.2.4 Regulatory framework
      • 7.1.2.5 Reimbursement scenario
      • 7.1.2.6 U.S. T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.1.3 Canada
      • 7.1.3.1 Key country dynamics
      • 7.1.3.2 Target disease prevalence
      • 7.1.3.3 Competitive scenario
      • 7.1.3.4 Regulatory framework
      • 7.1.3.5 Reimbursement scenario
      • 7.1.3.6 Canada T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.2 Europe
    • 7.2.1 SWOT Analysis
      • 7.2.1.1 Europe T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.2.2 Germany
      • 7.2.2.1 Key country dynamics
      • 7.2.2.2 Target disease prevalence
      • 7.2.2.3 Competitive scenario
      • 7.2.2.4 Regulatory framework
      • 7.2.2.5 Reimbursement scenario
      • 7.2.2.6 Germany T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.2.3 UK
      • 7.2.3.1 Key country dynamics
      • 7.2.3.2 Target disease prevalence
      • 7.2.3.3 Competitive scenario
      • 7.2.3.4 Regulatory framework
      • 7.2.3.5 Reimbursement scenario
      • 7.2.3.6 UK T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.2.4 France
      • 7.2.4.1 Key country dynamics
      • 7.2.4.2 Target disease prevalence
      • 7.2.4.3 Competitive scenario
      • 7.2.4.4 Regulatory framework
      • 7.2.4.5 Reimbursement scenario
      • 7.2.4.6 France T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.2.5 Italy
      • 7.2.5.1 Key country dynamics
      • 7.2.5.2 Target disease prevalence
      • 7.2.5.3 Competitive scenario
      • 7.2.5.4 Regulatory framework
      • 7.2.5.5 Reimbursement scenario
      • 7.2.5.6 Italy T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.2.6 Spain
      • 7.2.6.1 Key country dynamics
      • 7.2.6.2 Target disease prevalence
      • 7.2.6.3 Competitive scenario
      • 7.2.6.4 Regulatory framework
      • 7.2.6.5 Reimbursement scenario
      • 7.2.6.6 Spain T-cell therapy market estimates and f.orecasts, 2018 - 2030 (USD Million)
    • 7.2.7 Denmark
      • 7.2.7.1 Key country dynamics
      • 7.2.7.2 Target disease prevalence
      • 7.2.7.3 Competitive scenario
      • 7.2.7.4 Regulatory framework
      • 7.2.7.5 Reimbursement scenario
      • 7.2.7.6 Denmark T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.2.8 Sweden
      • 7.2.8.1 Key country dynamics
      • 7.2.8.2 Target disease prevalence
      • 7.2.8.3 Competitive scenario
      • 7.2.8.4 Regulatory framework
      • 7.2.8.5 Reimbursement scenario
      • 7.2.8.6 Sweden T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.2.9 Norway
      • 7.2.9.1 Key country dynamics
      • 7.2.9.2 Target disease prevalence
      • 7.2.9.3 Competitive scenario
      • 7.2.9.4 Regulatory framework
      • 7.2.9.5 Reimbursement scenario
      • 7.2.9.6 Norway T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.2.10 Rest Of Europe T-Cell Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.3 Asia Pacific
    • 7.3.1 SWOT analysis
      • 7.3.1.1 Key Region Dynamics
      • 7.3.1.2 Asia Pacific T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.3.2 Japan
      • 7.3.2.1 Target disease prevalence
      • 7.3.2.2 Competitive scenario
      • 7.3.2.3 Regulatory framework
      • 7.3.2.4 Reimbursement scenario
      • 7.3.2.5 Japan T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.3.3 China
      • 7.3.3.1 Target disease prevalence
      • 7.3.3.2 Competitive scenario
      • 7.3.3.3 Regulatory framework
      • 7.3.3.4 Reimbursement scenario
      • 7.3.3.5 China T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.3.4 India
      • 7.3.4.1 Target disease prevalence
      • 7.3.4.2 Competitive scenario
      • 7.3.4.3 Regulatory framework
      • 7.3.4.4 Reimbursement scenario
      • 7.3.4.5 India T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.3.5 South Korea
      • 7.3.5.1 Target disease prevalence
      • 7.3.5.2 Competitive scenario
      • 7.3.5.3 Regulatory framework
      • 7.3.5.4 Reimbursement scenario
      • 7.3.5.5 South Korea T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.3.6 Australia
      • 7.3.6.1 Target disease prevalence
      • 7.3.6.2 Competitive scenario
      • 7.3.6.3 Regulatory framework
      • 7.3.6.4 Reimbursement scenario
      • 7.3.6.5 Austrlia T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.3.7 Thailand
      • 7.3.7.1 Target disease prevalence
      • 7.3.7.2 Competitive scenario
      • 7.3.7.3 Regulatory framework
      • 7.3.7.4 Reimbursement scenario
      • 7.3.7.5 Thailand T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.3.8 Rest Of Asia Pacific T-Cell Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.4 Latin America
    • 7.4.1 SWOT Analysis
    • 7.4.2 Key Regional Dynamics
      • 7.4.2.1 Latin America T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.4.3 Brazil
      • 7.4.3.1 Target disease prevalence
      • 7.4.3.2 Competitive scenario
      • 7.4.3.3 Regulatory framework
      • 7.4.3.4 Reimbursement scenario
      • 7.4.3.5 Brazil T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.4.4 Mexico
      • 7.4.4.1 Target disease prevalence
      • 7.4.4.2 Competitive scenario
      • 7.4.4.3 Regulatory framework
      • 7.4.4.4 Reimbursement scenario
      • 7.4.4.5 Mexico T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.4.5 Argentina
      • 7.4.5.1 Target disease prevalence
      • 7.4.5.2 Competitive scenario
      • 7.4.5.3 Regulatory framework
      • 7.4.5.4 Reimbursement scenario
      • 7.4.5.5 Argentina T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.4.6 Rest Of Latam T-Cell Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5 Middle East & Africa (MEA)
    • 7.5.1 SWOT Analysis
    • 7.5.2 KEY regional Dynamics
      • 7.5.2.1 Middle East & Africa T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.5.3 South Africa
      • 7.5.3.1 Target disease prevalence
      • 7.5.3.2 Competitive scenario
      • 7.5.3.3 Regulatory framework
      • 7.5.3.4 Reimbursement scenario
      • 7.5.3.5 Brazil T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.5.4 Saudi Arabia
      • 7.5.4.1 Target disease prevalence
      • 7.5.4.2 Competitive scenario
      • 7.5.4.3 Regulatory framework
      • 7.5.4.4 Reimbursement scenario
      • 7.5.4.5 Saudi Arabia T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.5.5 UAE
      • 7.5.5.1 Target disease prevalence
      • 7.5.5.2 Competitive scenario
      • 7.5.5.3 Regulatory framework
      • 7.5.5.4 Reimbursement scenario
      • 7.5.5.5 UAE T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.5.6 Kuwait
      • 7.5.6.1 Target disease prevalence
      • 7.5.6.2 Competitive scenario
      • 7.5.6.3 Regulatory framework
      • 7.5.6.4 Reimbursement scenario
      • 7.5.6.5 Kuwait T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.5.7 Rest of MEA T-cell therapy market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8 Competitive Landscape

  • 8.1 Strategy Framework
  • 8.2 Company Profiles
    • 8.2.1 Novartis AG
      • 8.2.1.1 Company overview
      • 8.2.1.1.1 AveXis, Inc.
      • 8.2.1.2 Financial performance
      • 8.2.1.3 Product benchmarking
      • 8.2.1.4 Strategic initiatives
    • 8.2.2 Gilead Sciences
      • 8.2.2.1 Company overview
      • 8.2.1.1.1 Kite Pharma
      • 8.2.2.2 Financial performance
      • 8.2.2.3 Product benchmarking
      • 8.2.2.4 Strategic initiatives
    • 8.2.3 bluebird bio, Inc.
      • 8.2.3.1 Company overview
      • 8.2.3.2 Financial performance
      • 8.2.3.3 Product benchmarking
      • 8.2.3.4 Strategic initiatives
    • 8.2.4 TCR2 Therapeutics Inc
      • 8.2.4.1 Company overview
      • 8.2.4.2 Financial performance
      • 8.2.4.3 Product benchmarking
      • 8.2.4.4 Strategic initiatives
    • 8.2.5 Sorrento Therapeutics
      • 8.2.5.1 Company overview
      • 8.2.5.2 Product benchmarking
      • 8.2.5.3 Strategic initiatives
    • 8.2.6 Fate Therapeutics
      • 8.2.6.1 Company overview
      • 8.2.6.2 Financial performance
      • 8.2.6.3 Product benchmarking
      • 8.2.6.3 Strategic initiatives
    • 8.2.7 Merck KGaA
      • 8.2.7.1 Company overview
      • 8.2.7.2 Financial performance
      • 8.2.7.3 Product benchmarking
      • 8.2.7.3 Strategic initiatives
    • 8.2.8 Pfizer Inc.
      • 8.2.8.1 Company overview
      • 8.2.8.2 Financial performance
      • 8.2.8.3 Product benchmarking
      • 8.2.8.4 Strategic initiatives
    • 8.2.9 Amgen
      • 8.2.9.1 Company overview
      • 8.2.9.2 Financial performance
      • 8.2.9.3 Product benchmarking
      • 8.2.9.4 Strategic initiatives
    • 8.2.10 Celgene Corporation
      • 8.2.10.1 Company overview
      • 8.2.10.1.1 Juno Therapeutics
      • 8.2.10.2 Financial performance
      • 8.2.10.3 Product benchmarking
      • 8.2.10.4 Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 4 Global T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 5 Global T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 6 Global T-Cell Therapy Market by Region, 2018 - 2030 (USD Million)
  • Table 7 North America T-Cell Therapy Market by Country, 2018 - 2030 (USD Million)
  • Table 8 North America T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 9 North America T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 10 North America T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 11 U.S. T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 12 U.S. T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 13 U.S. T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 14 Canada T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 15 Canada T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 16 Canada T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 17 Europe T-Cell Therapy Market by Country, 2018 - 2030 (USD Million)
  • Table 18 Europe T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 19 Europe T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 20 Europe T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 21 Germany T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 22 Germany T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 23 Germany T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 24 U.K. T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 25 U.K. T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 26 U.K. T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 27 France T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 28 France T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 29 France T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 30 Italy T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 31 Italy T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 32 Italy T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 33 Spain T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 34 Spain T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 35 Spain T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 36 Denmark T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 37 Denmark T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 38 Denmark T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 39 Sweden T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 40 Sweden T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 41 Sweden T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 42 Norway T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 43 Norway T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 44 Norway T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific T-Cell Therapy Market by Country, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 49 China T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 50 China T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 51 China T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 52 Japan T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 53 Japan T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 54 Japan T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 55 India T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 56 India T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 57 India T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 58 South Korea T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 59 South Korea T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 60 South Korea T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 61 Australia T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 62 Australia T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 63 Australia T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 64 Thailand T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 65 Thailand T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 66 Thailand T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 67 Latin America T-Cell Therapy Market by Country, 2018 - 2030 (USD Million)
  • Table 68 Latin America T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 69 Latin America T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 70 Latin America T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 71 Brazil T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 72 Brazil T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 73 Brazil T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 74 Mexico T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 75 Mexico T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 76 Mexico T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 77 Argentina T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 78 Argentina T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 79 Argentina T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa T-Cell Therapy Market by Country, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 83 Middle East & Africa T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 84 South Africa T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 85 South Africa T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 86 South Africa T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 89 Saudi Arabia T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 90 UAE T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 91 UAE T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 92 UAE T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 93 Kuwait T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 94 Kuwait T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 95 Kuwait T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 T-Cell Therapy, Market Segmentation
  • Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 9 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 10 Penetration & Growth Prospect Mapping
  • Fig. 11 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 12 Porter's Five Forces Analysis
  • Fig. 13 Market Penetration Vs Growth Prospect Mapping, 2021
  • Fig. 14 Regional Marketplace: Key Takeaways
  • Fig. 15 Global T-Cell Therapy Market for Commercialized,2018 - 2030 (USD Million)
  • Fig. 16 Global T-Cell Therapy Market for Research, 2018 - 2030 (USD Million)
  • Fig. 17 Global T-Cell Therapy Market for In-Situ Hybridization Diagnostics, 2018 - 2030 (USD Million)
  • Fig. 18 Global T-Cell Therapy Market for CAR T Cell Therapy, 2018 - 2030 (USD Million)
  • Fig. 19 Global T-Cell Therapy Market for T Cell Receptor (TCR)-based,2018 - 2030 (USD Million)
  • Fig. 20 Global T-Cell Therapy Market for Tumor Infiltrating Lymphocytes (TIL)-based, 2018 - 2030 (USD Million)
  • Fig. 21 Global T-Cell Therapy Market for Hematologic Malignancies,2018 - 2030 (USD Million)
  • Fig. 22 Global T-Cell Therapy Market for Lymphoma, 2018 - 2030 (USD Million)
  • Fig. 23 Global T-Cell Therapy Market for Leukemia, 2018 - 2030 (USD Million)
  • Fig. 24 Global T-Cell Therapy Market for Myeloma, 2018 - 2030 (USD Million)
  • Fig. 25 Global T-Cell Therapy Market for Solid Tumors, 2018 - 2030 (USD Million)
  • Fig. 26 Global T-Cell Therapy Market for Melanoma, 2018 - 2030 (USD Million)
  • Fig. 27 Global T-Cell Therapy Market for Brain and central nervous system, 2018 - 2030 (USD Million)
  • Fig. 28 Global T-Cell Therapy Market for Liver cancer,2018 - 2030 (USD Million)
  • Fig. 29 Global T-Cell Therapy Market for Others,2018 - 2030 (USD Million)
  • Fig. 30 Global T-Cell Therapy Market for Other Indications, 2018 - 2030 (USD Million)
  • Fig. 31 Regional Outlook, 2021 & 2030
  • Fig. 32 North America T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 33 U.S. T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 34 Canada T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 35 Europe T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 36 Germany T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 37 U.K. T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 38 France T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 39 Italy T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 40 Spain T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 41 Denmark T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 42 Sweden T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 43 Norway T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 44 Asia Pacific T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 45 Japan T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 46 China T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 47 India T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 48 Australia T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 49 South Korea T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 50 Thailand T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 51 Latin America T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 52 Brazil T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 53 Mexico T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 54 Argentina T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 55 Middle East and Africa T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 56 South Africa T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 57 Saudi Arabia T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 58 UAE T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 59 Kuwait T-Cell Therapy Market 2018 - 2030 (USD Million)